Pet Cancer Therapeutics Market Size By Medicine Type (Chemotherapy Drugs and Vaccines), By Species (Dogs and Cats), By Cancer Type (Lymphoma, Mast Cell Cancer Tumors, Melanoma, Mammary and Squamous Cell Cancer), Regional Outlook (U.S., Canada, Germany, UK, Spain, Italy, France, China, Japan, India, Australia, Brazil, Mexico), Technology Development, Competitive Landscape & Forecast, 2017 – 2024
Published Date: August 2017 | 95 Pages | Report ID: GMI2017 Report Format: PDF
Pet Cancer Therapeutics Market valued above USD 140 million in 2016 and is projected to witness more than 10% CAGR from 2017 to 2024.
U.S Pet cancer therapeutics market, by medicine type, 2013 - 2024 (USD Million)
Increasing trend of pet adoption such as dogs and cats owing to improved economic status of people will drive pet cancer therapeutics market size. Furthermore, rising prevalence of pet cancer and growing pet healthcare expenditure will stimulate industry growth.
Growing R&D initiatives to treat pet cancer will result into launch of novel products in the market over the forecast years. Industry players with robust product pipelines will continue to expand the market share with their innovative treatments.
The adverse effects of pet cancer drugs and lack of awareness about pet diseases among the pet owners will restrain business growth. High cost of pet cancer therapeutics will further hamper pet health in most developing as well as under-developed countries across the world.
Pet Cancer Therapeutics Market, By Medicine Type
Chemotherapy drugs held the highest pet cancer therapeutics market share in 2016. Launch of new drugs for treatment of various cancers is anticipated to augment pet cancer therapeutics market share over the forecast years.
Pet cancer vaccines are comparatively newer and lesser practiced medicine than chemotherapy; therefore, holds a relatively small market share. With more number of vaccines in pipeline the pet cancer therapeutics market share should at healthy CAGR over the forecast years.
Pet Cancer Therapeutics Market, By Species
Dog cancer therapeutics market held largest revenue share in 2016, owing to its early inception and high number of marketed drugs and vaccines for dog cancer treatment. Over 80% of pet cancer pipeline drugs contains medication for dogs; therefore, dog cancer therapeutics market will grow with higher CAGR as compared to cats.
Low number of medicines for treatment of cancer in cats have resulted into a very low market share. However, with specialized cat cancer medicine in pipeline, the market is likely to grow at a considerable CAGR over the forecast years.
Pet Cancer Therapeutics Market, Cancer Type
Lymphoma is the most common pet cancer type, especially in dogs. However, until the year 2016, there had been hardly any medicine available for dog cancer treatment. Many companies have robust drugs pipeline for lymphoma treatment which is anticipated to boost industry growth over the forecast years.
Mast cell cancer held largest pet cancer therapeutics market share, owing to availability of drugs for its treatment. However, shifting focus of companies from mast cell cancer to other cancer treatments may slower down the mast cell cancer therapeutics market growth over the forecast timeframe.
Pet Cancer Therapeutics Market, By Region
North America pet cancer therapeutics market accounted for more than 80% of the overall revenue share in 2016, owing to the regional presence of several established players. Early product adoption and advances in product development to address different pet cancers will drive industry growth.
UK pet cancer therapeutics market held largest regional share in 2016. Pet cancer vaccines were available in most of the European regions before chemotherapy drugs. Vaccines market is likely to witness strong growth owing to introduction of new vaccines over the forecast period.
India pet cancer therapeutics market is projected to witness over 12% CAGR over the forecast timeframe. Increasing awareness, availability of various pet caner medicine and increasing pet healthcare spending will drive the business growth.
Competitive Market Share
Some of the notable industry players include Zoetis, Merial, Aratana Therapeutics, AB Science, Vetivax, VetDC, Regeneus and Karyopharms Verdinexor. The established players hold significant market share and have their presence in several regions. Moderate level of competition is seen among the companies as they have targeted different pet cancers with their unique product offering. New product launches, strategic mergers and acquisition, and geographic expansion are some of the strategies practiced to manifest competitive advantage.
Pet Cancer Therapeutics Industry Background
The Pet cancer therapeutics sector is a relatively new compared to other pet healthcare sectors. Over the past 8 years, it has evolved rapidly in terms of product development and coverage of broad pool of cancers that affect pet animals. The industry has been consistently dominated by established big pharmaceuticals companies. However, new specialised pet cancer therapeutics companies have been entering into the market in recent times.
What Information does this report contain?
Why Global Market Insights?Comprehensive Research
- All-inclusive coverage
- In-depth and granular data (ex: information for 8 to 15 countries, with clients open to add to this list, in each report)
- Penetrative insights & latest trends
- Offers holistic understanding of the market
- Unique methodology
- Iterative in nature to eliminate errors
- Detailed methodology, scope, assumptions and data sources available for reference
- Committed to making a positive difference for our clients
- Given the nature of this industry, we are committed to ensure that our clients get maximum return on their investment in our services
- Every purchase comes with an option to obtain additional information:
- up to 10% of the original cost
- 45-minute analyst tele-call to obtain further clarity on the market.
- Global Market Insights, Inc. strictly adheres to PCI-DSS security norms.
- Only PCI-DSS compliant payment methods used for highest level of client data security